Judy E. Kim, MD
November/December 2018—How home-based telemedicine could be transformational for patients with AMD.
S.K. Steven Houston III, MD; and John B. Miller, MD
November/December 2018—It’s anyone’s guess what tomorrow’s ORs will look like. Here, these authors build from their imaginations.
Megan A. Kasetty, BS; Jay C. Wang, MD; and John B. Miller, MD
November/December 2018—Recent advances in this technology may help streamline screening and examinations and allow retina specialists to diagnose disease in patients remotely.
October 2018—Apellis Begins PHASE 3 Trials FOR COMPLEMENT INHIBITION in GA
Two phase 3 trials of a complement-inhibiting peptide have begun, assessing the safety and efficacy of the com…
September 2018—Aflibercept Label Now Includes 12-Week Dosing Interval for AMD
The US FDA in August approved an updated label for aflibercept (Eylea, Regeneron), adding every-12-week injec…
July/August 2018—NOVARTIS PLANS TO SPIN OFF ALCON
Novartis plans to spin off its eye care devices division, Alcon, into a separately traded standalone company, the company announced in June…
David S. Boyer, MD
July/August 2018—The cornea and sclera stand in the way of this more convenient, less invasive drug delivery modality.
Glenn J. Jaffe, MD
July/August 2018—An injectable sustained drug delivery system may have advantages over existing options.
